PARKINSON DISEASE (Disorder)cTDCSinPDNCT07548801
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
A study testing cTDCS in people with PARKINSON DISEASE (Disorder), run by Université Libre de Bruxelles at 1 site in Belgium.
Trial summary
Background \& Rationale: Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PARKINSON DISEASE (Disorder)
- What is being tested?
- cTDCS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteBelgium
- Study dates
- 24 Sep 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with mild to moderate PD MDS-UPDRS part 1III or between 1 and 3 on Hoehn and Yahr score
- Patients > 18 years of agE
- Patients who have signed written informed consent
Who cannot join
- Pregnant women
- Patients ≤ 18 years of age
- Presence of intracranial metallic hardware (e.g., vascular clips, orthopedic material)
- Presence of an implanted electronic device (e.g., pacemaker, cochlear implants, deep brain stimulator)
- History of epileptic seizures
- Active or past neurological condition affecting upper limb control (e.g., stroke, degenerative disease, tumor, traumatic sequelae), or any neuromuscular (e.g., upper limb polyneuropathy, myopathy) or orthopedic condition impairing upper limb motor control
- Subject unable to understand or perform the required motor tasks
- Psychotropic polypharmacy (regular use of neuroleptics, anti-epileptics, benzodiazepines, etc.)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Can Cerebellar Transcranial Direct Current Stimulation be Regarded as a Rational Therapeutic Option for Treating Parkinson's Disease ?
Background \& Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Read more
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
- Conditions
- PARKINSON DISEASE (Disorder)
- Being tested
- cTDCS
- Keywords
- Parkinson's disease, cerebellar transcranial direct current stimulation, MDS-UPDRS, CCAS scale
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cTDCSDevice
anodal cTDCS
cTDCSDevice
cathodal cTDCS
| Study group | Role | What they receive |
|---|---|---|
| anodal cTDCS group | Experimental | Not described Receives: Device: cTDCS |
| cathodal cTDCS group | Active comparator | Not described Receives: Device: cTDCS |
What is being measured
The primary outcome is the main question the study is designed to answer.
MDS-UPDRS (Unit on a scale)
MDS-UPDRS Part III MDS-UPDRS Part I, II and IV
Measured: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)
CCAS (Unit on a scale)
CCAS scale
Measured: day 1 and day 10
Secondary outcomes (7)
Feasibility and tolerability of ctDCS (Unit on a scale)
participant-reported outcomes regarding the ease of self-administration and the presence of side effects are collected through a dedicated questionnaire.
Measured: from day 1 to day 10
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Generalized Anxiety Disorder-7 (GAD-7)
Measured: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Patient Health Questionnaire-9 (PHQ-9 )
Measured: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by Parkinson's Disease Questionnaire-39 (PDQ-39)
Measured: day 1 and day 40
Scale evaluation anxiety (Unit on a scale)
anxiety as evaluated by Beck Anxiety Inventory (BAI)
Measured: day 1 and day 40
Scale evaluating depression (Unit on a scale)
depression as evaluated by Beck Depression Inventory (BDI)
Measured: day 1 and day 40
Quality of life (Unit on a scale)
quality of life as evaluated by European Quality of Life 5 Dimensions (EQ-5D)
Measured: day 1 and day 40
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2026
- Study start24 Sep 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for PARKINSON DISEASE (Disorder)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Three months post-stimulation, patients will cross over to the other study group
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Libre de Bruxelles
- Sponsor type
- University, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Responsible party
- Principal investigator, Pierre Cabaraux, Université Libre de Bruxelles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07548801
- Sponsor's protocol ID
- B40620224000258 ; P2024/328
- Acronym
- cTDCSinPD
- Status last verified
- Apr 2026
- First submitted
- 1 Apr 2026
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: anonymous.
Publications
Manto M, Argyropoulos GPD, Bocci T, Celnik PA, Corben LA, Guidetti M, Koch G, Priori A, Rothwell JC, Sadnicka A, Spampinato D, Ugawa Y, Wessel MJ, Ferrucci R. Consensus Paper: Novel Directions and Next Steps of Non-invasive Brain Stimulation of the Cerebellum in Health and Disease. Cerebellum. 2022 Dec;21(6):1092-1122. doi: 10.1007/s12311-021-01344-6. Epub 2021 Nov 23.
PubMed 34813040Cabaraux P, Georgiev C, Destrebecq V, Supiot F, Munoz NY, Hakkak Moghadam Torbati A, Digileva D, Iannotta A, Yildiran Carlak E, Mongold S, Bourguignon M, Naeije G. Effects of anodal cerebellar transcranial direct current stimulation on motor symptoms and cerebellar inhibition in Parkinson's disease: A sham-controlled cross-over study. Parkinsonism Relat Disord. 2026 Mar;144:108202. doi: 10.1016/j.parkreldis.2026.108202. Epub 2026 Jan 28.
PubMed 41616661
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Cerebellar Transcranial Direct Current Stimulation be Regarded as a Rational Therapeutic Option for Treating Parkinson's Disease ?
- ClinicalTrials.gov ID
- NCT07548801
- Acronym / sponsor ID
- cTDCSinPD / B40620224000258 ; P2024/328
- Conditions
- PARKINSON DISEASE (Disorder)
- Keywords
- Parkinson's disease, cerebellar transcranial direct current stimulation, MDS-UPDRS, CCAS scale
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Université Libre de BruxellesUniversity, hospital or other
- Collaborators
- Fonds National de la Recherche Scientifique
- Study start
- 24 Sep 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 23 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background \& Rationale:
Treatment options for Parkinson's Disease (PD) often face challenges due to the variety of clinical subtypes, differing individual responses, and disease progression. Given its portability, affordability, safety, and ease of use, cerebellar transcranial direct current stimulation (ctDCS) presents as a promising option for home-based treatment with medical telemonitoring in the near future.
Study Procedures:
Participants are invited to complete questionnaires regarding quality of life, anxiety and depression, and symptoms related to their PD.
On the first day, they will be assessed using the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III for motor impairment and the Cerebellar Cognitive Affective Syndrome scale (CCAS) for cognitive impairment. Participants will then undergo an additional 8 days of at-home cTDCS stimulation. On the 10th day, they will be reassessed using the MDS-UPDRS III and CCAS. One month later, they will complete again the questionnaires regarding quality of life, anxiety, depression, and symptoms related to their PD.
Objective:
Consequently, the primary goal is to investigate the effectiveness of ctDCS in addressing both motor and non-motor symptoms of PD
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Three months post-stimulation, patients will cross over to the other study group
| Arm | Type | Receives |
|---|---|---|
| anodal cTDCS group | Experimental | Device: cTDCS |
| cathodal cTDCS group | Active comparator | Device: cTDCS |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients with mild to moderate PD MDS-UPDRS part 1III or between 1 and 3 on Hoehn and Yahr score
- Patients > 18 years of agE
- Patients who have signed written informed consent
Key exclusion criteria (8 listed)
- Pregnant women
- Patients ≤ 18 years of age
- Presence of intracranial metallic hardware (e.g., vascular clips, orthopedic material)
- Presence of an implanted electronic device (e.g., pacemaker, cochlear implants, deep brain stimulator)
- History of epileptic seizures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cTDCSanodal cTDCS | Device | anodal cTDCS group |
| cTDCScathodal cTDCS | Device | cathodal cTDCS group |
Primary outcome
MDS-UPDRS (Unit on a scale)
Time frame: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)
MDS-UPDRS Part III MDS-UPDRS Part I, II and IV
CCAS (Unit on a scale)
Time frame: day 1 and day 10
CCAS scale
7 secondary outcomes
Feasibility and tolerability of ctDCS (Unit on a scale)
Time frame: from day 1 to day 10
Scale evaluation anxiety (Unit on a scale)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
Time frame: day 1 and day 40
Scale evaluation anxiety (Unit on a scale)
Time frame: day 1 and day 40
Scale evaluating depression (Unit on a scale)
Time frame: day 1 and day 40
Quality of life (Unit on a scale)
Time frame: day 1 and day 40
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Background: PubMed 34813040Manto M, Argyropoulos GPD, Bocci T, Celnik PA, Corben LA, Guidetti M, Koch G, Priori A, Rothwell JC, Sadnicka A, Spampinato D, Ugawa Y, Wessel MJ, Ferrucci R. Consensus Paper: Novel Directions and Next Steps of Non-invasive Brain Stimulation of the Cerebellum in Health and Disease. Cerebellum. 2022 Dec;21(6):1092-1122. doi: 10.1007/s12311-021-01344-6. Epub 2021 Nov 23.
- Background: PubMed 41616661Cabaraux P, Georgiev C, Destrebecq V, Supiot F, Munoz NY, Hakkak Moghadam Torbati A, Digileva D, Iannotta A, Yildiran Carlak E, Mongold S, Bourguignon M, Naeije G. Effects of anodal cerebellar transcranial direct current stimulation on motor symptoms and cerebellar inhibition in Parkinson's disease: A sham-controlled cross-over study. Parkinsonism Relat Disord. 2026 Mar;144:108202. doi: 10.1016/j.parkreldis.2026.108202. Epub 2026 Jan 28.
- Individual participant dataSharing planned: No. anonymous.
Related trials for PARKINSON DISEASE (Disorder)
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing cTDCS in people with PARKINSON DISEASE (Disorder), run by Université Libre de Bruxelles at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MDS-UPDRS (Unit on a scale) (time frame: day 1 to day 10 (MDS-UPDRS III) day 1 to day 40 (MDS-UPDRS Part I, II and IV)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07548801, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.